Patents Represented by Attorney Peter J. Knudsen
  • Patent number: 7244412
    Abstract: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: July 17, 2007
    Assignee: Cedars-Sinai Medical Center
    Inventor: Henry C. Lin
  • Patent number: 7244709
    Abstract: Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: July 17, 2007
    Assignee: Nastech Pharamecutical Company Inc.
    Inventors: Steven C. Quay, Henry R. Costantino, Mary S. Kleppe, Ching-Yuan Li
  • Patent number: 7230005
    Abstract: The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing, or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose or carboxymethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: June 12, 2007
    Assignee: Controlled Chemicals, Inc.
    Inventors: Jules A. Shafer, Vladislav V. Telyatnikov, Zhiwei Guo
  • Patent number: 7229966
    Abstract: Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: June 12, 2007
    Assignee: Nastech Pharmaceutical Company Inc.
    Inventors: Steven C. Quay, Gordon Brandt, Mary S. Kleppe, Conor J. MacEvilly
  • Patent number: 7229636
    Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: June 12, 2007
    Assignee: Nastech Pharmaceutical Company Inc.
    Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
  • Patent number: 7186692
    Abstract: Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
    Type: Grant
    Filed: June 16, 2004
    Date of Patent: March 6, 2007
    Assignee: Nastech Pharmaceutical Company Inc.
    Inventors: Steven C. Quay, Gordon Brandt
  • Patent number: 7186691
    Abstract: Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: March 6, 2007
    Assignee: Nastech Pharmaceutical Company Inc.
    Inventors: Steven C. Quay, Gordon Brandt, Mary S. Kleppe, Conor J. MacEvilly
  • Patent number: 7166575
    Abstract: Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (Cmax) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: January 23, 2007
    Assignee: Nastech Pharmaceutical Company Inc.
    Inventor: Steven C Quay
  • Patent number: 7157426
    Abstract: Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: January 2, 2007
    Assignee: Nastech Pharmaceutical Company Inc.
    Inventors: Steven C. Quay, Gordon Brandt, Mary S. Kleppe, Conor J. MacEvilly
  • Patent number: 7081239
    Abstract: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: July 25, 2006
    Assignee: Cedars-Sinai Medical Center Burns and Allen Research Center
    Inventor: Henry C. Lin
  • Patent number: 6951682
    Abstract: Articles comprising substantially uniform porous coatings, which may be photopatterned, are provided. The use of such porous coatings increases the surface density of attached compounds within, for example, ligand arrays prepared by methods such as regionally selective solid-phase chemical synthesis. Arrays prepared using the porous coatings may be used within a variety of diagnostic and drug discovery assays.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: October 4, 2005
    Assignee: Syntrix Biochip, Inc.
    Inventor: John A. Zebala
  • Patent number: 6939712
    Abstract: The invention provides compositions and methods for muting expression of an endogenous gene in an animal cell, the muting resulting from providing a transgene to a cell. Expression of which transgene is undetectable. The transgene comprises the muting nucleic acid, which is substantially homologous to a portion of the endogenous gene. The portion of the endogenous gene provided on the transgene can be from the 5?-untranscribed end, from the 3? untranscribed end, from an exon or an intron in the coding portion, or from a portion that overlaps any of these portions. Methods are provided for obtaining muting nucleic acid, and for screening for molecules that can mute the gene, and for molecules that can alleviate muting of the gene.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: September 6, 2005
    Assignee: Impedagen, LLC
    Inventors: Mohammad B. Bahramian, Helmut Zarbl